Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report

PURPOSE: The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of vorinostat administered as a single agent and in combination 13-cis retinoic acid (13cRA) in children with refractory solid tumors; to evaluate the tolerabili...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Fouladi, Maryam, Park, Julie R., Stewart, Clinton F., Gilbertson, Richard J., Schaiquevich, Paula, Sun, Junfeng, Reid, Joel M., Ames, Matthew M., Speights, Roseanne, Ingle, Ashish M., Zwiebel, James, Blaney, Susan M., Adamson, Peter C.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2010
Предметы:
Original Reports
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917318/
https://ncbi.nlm.nih.gov/pubmed/20606092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.9119
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы